CCLA Investment Management Purchases 17,778 Shares of Stryker Corporation $SYK

CCLA Investment Management increased its position in Stryker Corporation (NYSE:SYK) by 4.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 401,936 shares of the medical technology company’s stock after buying an additional 17,778 shares during the quarter. Stryker makes up about 2.3% of CCLA Investment Management’s investment portfolio, making the stock its 15th largest position. CCLA Investment Management’s holdings in Stryker were worth $141,248,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Evermay Wealth Management LLC boosted its holdings in Stryker by 4.5% in the 4th quarter. Evermay Wealth Management LLC now owns 3,227 shares of the medical technology company’s stock worth $1,136,000 after buying an additional 139 shares during the period. Ledyard National Bank boosted its holdings in shares of Stryker by 9.3% during the 4th quarter. Ledyard National Bank now owns 1,913 shares of the medical technology company’s stock valued at $672,000 after purchasing an additional 163 shares during the last quarter. BIP Wealth LLC boosted its holdings in shares of Stryker by 149.0% during the 4th quarter. BIP Wealth LLC now owns 2,276 shares of the medical technology company’s stock valued at $800,000 after purchasing an additional 1,362 shares during the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter valued at about $212,000. Finally, Perfromance Wealth Partners LLC bought a new position in shares of Stryker during the 4th quarter valued at about $284,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $339.85 on Thursday. The company’s 50 day moving average is $355.78 and its 200 day moving average is $360.97. The company has a market cap of $130.16 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 1.94 and a beta of 0.92. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a twelve month low of $319.32 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the previous year, the firm posted $4.01 EPS. Stryker’s revenue was up 11.4% compared to the same quarter last year. On average, sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Wall Street Analyst Weigh In

Several research firms have commented on SYK. The Goldman Sachs Group set a $399.00 price objective on shares of Stryker in a report on Friday, January 9th. BTIG Research increased their price objective on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Robert W. Baird set a $437.00 price objective on shares of Stryker in a research report on Friday, January 30th. Evercore set a $390.00 price objective on shares of Stryker in a research report on Monday, January 5th. Finally, Needham & Company LLC raised their target price on shares of Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $425.56.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.